Cargando…
Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia
Autoimmune hemolytic anemia (AIHA) therapy may be associated with severe complications such as diabetes, hypertension, obesity, osteoporosis, peptic ulcers, infection, and some other diseases. To reduce those effects, we used low-dose rituximab, bortezomib and dexamethasone (LowR-BD regimen) to trea...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797600/ https://www.ncbi.nlm.nih.gov/pubmed/35089216 http://dx.doi.org/10.1097/MD.0000000000028679 |